Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9361685 | 0.81 | PDE10A (0.44) | TOP2ATOP2BPARP10PARP11PDGFRA | |
| SCHEMBL9705539 | 0.73 | PDGFRA (0.62) | PDGFRACLK4CA12CA1CA2 | |
| SCHEMBL32667946 | 0.71 | PDGFRB (0.77) | TOP2ATOP2BCYP1A2PDGFRAPDGFRB | |
| SCHEMBL2772360 | 0.71 | PDGFRB (0.77) | TOP2ATOP2BCYP1A2PDGFRAPDGFRB | |
| SCHEMBL17215087 | 0.69 | CYP1A2 (0.51) | TOP2ATOP2BCYP1A2PARP10PARP11 | |
| SCHEMBL18551805 | 0.69 | CYP1A2 (0.51) | TOP2ATOP2BCYP1A2PARP10PARP11 | |
| SCHEMBL15070812 | 0.68 | L3MBTL1 (0.57) | TOP2ATOP2BCYP1A2PARP10PARP11 | |
| SCHEMBL23555381 | 0.67 | PDGFRB (0.66) | CYP1A2PDGFRAPDGFRBCLK4MAP4K4 | |
| SCHEMBL8370258 | 0.67 | PDGFRB (0.66) | CYP1A2PDGFRAPDGFRBCLK4MAP4K4 | |
| SCHEMBL7269315 | 0.67 | PDE3B (0.49) | PDGFRACLK4MAPK8CDK5CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110244057-A1 | COMBINATION THERAPIES WITH TOPIRAMATE FOR SEIZURES, RESTLESS LEGS SYNDROME, AND OTHER NEUROLOGICAL CONDITIONS | EHRENBERG BRUCE L | 2011-10-06 | — | — | US | disclosed |
| WO-2010036977-A2 | COMBINATION THERAPIES WITH TOPIRAMATE FOR SEIZURES, RESTLESS LEGS SYNDROME, AND OTHER NEUROLOGICAL CONDITIONS | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-RE39300-E1 | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE OF VIRGINIA (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0938305-B8 | METHOD OF ALLEVIATING PAIN BY MEANS OF COMBINING TRAMADOL WITH AN NMDA ANTAGONIST | ENDO PHARMACEUTICALS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-0938305-B1 | METHOD OF ALLEVIATING PAIN BY MEANS OF COMBINING TRAMADOL WITH AN NMDA ANTAGONIST | ALGOS PHARM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-0942752-B1 | ANTICONVULSANT CONTAINING COMPOSITION FOR TREATING NEUROPATHIC PAIN | ALGOS PHARM CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-0778770-B1 | COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER | UNIV VIRGINIA COMMONWEALTH (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6406716-B2 | Anticonvulsant containing composition for treating neuropathic pain | ENDO PHARMACEUTICALS INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | disclosed |
| US-20010008889-A1 | Anticonvulsant containing composition for treating neuropathic pain | ENDO PHARMACEUTICALS INC. | 2001-07-19 | — | — | US | disclosed |
| US-5654281-A | Inhibiting the development of tolerance to and/or dependence on an addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0778770-A1 | COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5556838-A | BLOCKING N-METHYLASPARTATE RECEPTORS TO PREVENT ADDICTION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-09-17 | — | — | US | disclosed |
| US-5502058-A | Method for the treatment of pain | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1996007412-A1 | COMPOSITION ALLEVIATING PAIN, CONTAINING A NON-NARCOTIC ANALGESIC AND AN ANALGESIA ENHANCER | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0615749-A2 | Use of NMDA antagonists for the treatment of pain | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-09-21 | — | — | EP | disclosed |
| EP-0365863-B1 | Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors | MERRELL DOW PHARMA (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0608893-A1 | Inhibiting the development of tolerance to and/or dependence on an additive substance | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-08-03 | — | — | EP | disclosed |
| US-5321012-A | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance | VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL COLLEGE (US) | 1994-06-14 | — | — | US | disclosed |
| US-4990519-A | Antiasthma, hypotensive agents, bronchodilator agents | MERRELL DOW PHARMACEUTICALS (US) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110244057-A1 | COMBINATION THERAPIES WITH TOPIRAMATE FOR SEIZURES, RESTLESS LEGS SYNDROME, AND OTHER NEUROLOGICAL CONDITIONS | CACNA1A, GRM2, GRIN2B | TOP2A 2582/4885TOP2B 2471/4885CYP1A2 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.